Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer.

ABSTRACT:

Background

Consolidation durvalumab improved overall survival (OS) in locally advanced non-small cell lung cancer (LA-NSCLC) treated with chemoradiotherapy (CRT) in the PACIFIC trial; however, pneumonitis was increased with durvalumab. We sought to examine real-world outcomes with the PACIFIC paradigm, especially factors associated with pneumonitis, using a multi-institutional review.

Methods

Patients with LA-NSCLC treated with CRT followed by durvalumab from January 2017-February 2019 were identified at 2 institutions. We characterized demographics, tumor factors, radiotherapy, and duration of durvalumab. We examined pneumonitis outcomes including re-challenge success, with secondary endpoints of progression-free survival (PFS) and OS.

Results

Thirty-four patients we

SUBMITTER: Hassanzadeh C 

PROVIDER: S-EPMC7711405 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature